Cannabidiol: pharmacology and therapeutic targets
SC Britch, S Babalonis, SL Walsh - Psychopharmacology, 2021 - Springer
Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …
Cannabidiol adverse effects and toxicity
MA Huestis, R Solimini, S Pichini… - Current …, 2019 - ingentaconnect.com
Background: Currently, there is a great interest in the potential medical use of cannabidiol
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Summary Background Patients with Lennox-Gastaut syndrome, a rare, severe form of
epileptic encephalopathy, are frequently treatment resistant to available medications. No …
epileptic encephalopathy, are frequently treatment resistant to available medications. No …
Labeling accuracy of cannabidiol extracts sold online
Methods| Internet searches (keywords: CBD, cannabidiol, oil, tincture, vape) were performed
between September 12, 2016, and October 15, 2016, to identify CBD products available for …
between September 12, 2016, and October 15, 2016, to identify CBD products available for …
Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled …
YL Hurd, S Spriggs, J Alishayev… - American Journal of …, 2019 - Am Psychiatric Assoc
Objective: Despite the staggering consequences of the opioid epidemic, limited nonopioid
medication options have been developed to treat this medical and public health crisis. This …
medication options have been developed to treat this medical and public health crisis. This …
[HTML][HTML] Cannabinoids in the treatment of epilepsy: hard evidence at last?
E Perucca - Journal of epilepsy research, 2017 - ncbi.nlm.nih.gov
The interest in cannabis-based products for the treatment of refractory epilepsy has
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …
Assessment of orally administered Δ9-tetrahydrocannabinol when coadministered with cannabidiol on Δ9-tetrahydrocannabinol pharmacokinetics and …
Importance Controlled clinical laboratory studies have shown that cannabidiol (CBD) can
sometimes attenuate or exacerbate the effects ofΔ9-tetrahydrocannabinol (Δ9-THC). No …
sometimes attenuate or exacerbate the effects ofΔ9-tetrahydrocannabinol (Δ9-THC). No …
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
S Bonaccorso, A Ricciardi, C Zangani, S Chiappini… - Neurotoxicology, 2019 - Elsevier
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review
The recent liberalisation of cannabis regulation has increased public and scientific debate
about its potential benefits and risks. A key focus has been the extent to which cannabidiol …
about its potential benefits and risks. A key focus has been the extent to which cannabidiol …
Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol
The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its
psychotropic and mind-altering side effects for millennia. There has been growing attention …
psychotropic and mind-altering side effects for millennia. There has been growing attention …